Cardiol Therapeutics Inc
Commented by Fabian Lorenz on December 21st, 2022 | 08:48 CET
BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?
Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.
Read
Commented by Armin Schulz on December 12th, 2022 | 10:20 CET
BioNTech, va-Q-tec, Cardiol Therapeutics, Ambrx Biopharma - Biotech second-line stocks explode
For investors in biotech stocks, 2022 was often a year to forget. After the Corona hype, the market clouded over significantly, in part due to rising interest rates. December is the time of year when investors can make adjustments to their portfolio, thereby reducing their tax burden for the year ahead. This year is no exception, yet three stocks shot up last Friday. That is unusual during tax loss season. We look at the three high flyers and BioNTech, a big player in the biotech sector.
Read
Commented by Nico Popp on December 8th, 2022 | 09:05 CET
Where the money is made: BioNTech, Novavax, Cardiol Therapeutics
While the first federal states in Germany are lifting the mask requirement on public transport, suppliers of vaccines and medicines are far from going back to normal. Even corona vaccines are in high demand. While there is a shortage of antipyretics and medication in this country, especially for children, innovative companies are already addressing the next challenges. We explain where investors can make money.
Read
Commented by Stefan Feulner on November 28th, 2022 | 10:41 CET
SynBiotic SE, Cardiol Therapeutics, Canopy Growth - Like hitting the jackpot
The final draft of the German government's key issues paper on the legalization of cannabis in Germany is ready, and final approval is likely to be a mere formality. For the companies concerned, this is equivalent to winning the lottery. The global cannabis market is expected to grow by 13.9% annually to USD 64.91 billion between 2022 and 2027. However, these profit increases have yet to reach the stock market. Some companies, for example, are trading below cash, while others lost more than 90% of their value in the correction that has been underway since 2019.
Read
Commented by Armin Schulz on November 7th, 2022 | 10:31 CET
BioNTech, Cardiol Therapeutics, Bayer - Strong growth in the pharmaceutical industry over the coming years
Demographic change is bringing new customers to pharmaceutical and biotech companies. Worldwide, the population is getting older, and with it, the number of patients with dementia, cancer and heart disease. Experts estimate that the population over 65 will increase steadily until 2050. The 'pill gap' will start to have a real impact from 2030, and then the proportion of the aging population will rise again in proportion. Accordingly, all healthcare companies will see growth as the number of customers grows. So today, we look at three companies committed to better patient health.
Read
Commented by André Will-Laudien on October 31st, 2022 | 13:31 CET
Top biotech shares - Now on the up: Bayer, Cardiol Therapeutics, BioNTech, Pfizer
The fight against the two "common diseases" of cancer and cardiovascular disease continues with a major infusion of resources. In early 2022, President Biden announced a new edition of the "Cancer Moonshot" and named new goals: To halve the cancer death rate within 25 years and significantly improve the lives of people with cancer. The most common cause of death in Germany, on the other hand, is cardiovascular disease. With around 338,000 deaths in 2020, it accounted for more than a third of the 985,500 deaths. The second most common cause of death was primarily cancer, followed by diseases of the respiratory system. The biotech industry thus continues to face major challenges. Who is well positioned?
Read
Commented by Stefan Feulner on October 26th, 2022 | 11:28 CEST
Biogen, Cardiol Therapeutics, Evotec - Brilliant results
The reporting season for the third quarter is in full swing and is creating a thoroughly positive mood. For example, the software group SAP posted surprisingly strong growth in its cloud business in the third quarter, and its operating result was better than forecast. Positive signals are also coming from the biotech sector, which has been badly battered in recent months. After the horrendous share price losses, this sector, in particular, offers attractive long-term entry levels.
Read
Commented by Nico Popp on October 19th, 2022 | 13:52 CEST
Biotech funds looking over their shoulders: Bavarian Nordic, Cardiol Therapeutics, Valneva
A recent study by Accenture shows that consumers are not willing to reduce their spending on health and wellness - even if things are not going well economically. Despite uncertainties, respondents see spending in the areas of "health" and "fitness" as "essential." Those who pay for these areas are also likely to want to exhaust all options when it comes to health insurance benefits, such as medications and vaccines. Informed patients and consumers put pressure on their doctors when new therapies are available. Health insurers, who are also in competition with each other, are taking this into account. We highlight three biotech stocks and do the investment check.
Read
Commented by Fabian Lorenz on October 12th, 2022 | 11:33 CEST
TUI share soon to be a penny stock? BASF, BioNTech, Cardiol Therapeutics - buy or sell?
Buy or sell? It is not only the BASF share that is currently the subject of clearly differing opinions. While the gas price brake plans on Monday caused euphoria among investors and correspondingly rising prices for the shares of the chemical company, analysts from Goldman Sachs and Morgan Stanley continue to express pessimism. Experts are similarly cautious about the prospects for TUI. UBS even sees the share of the tourism group on the way to becoming a penny stock. Analysts are more optimistic about BioNTech, but the share is not making any headway at the moment. In contrast, experts see massive upside potential in the biotech gem Cardiol Therapeutics. Cash is now equal to market capitalization, and drug development is making progress.
Read
Commented by Stefan Feulner on October 6th, 2022 | 11:43 CEST
Nordex, Cardiol Therapeutics, Rock Tech Lithium - Great opportunities in bombed-out stocks
The market correction of recent months due to geopolitical conflicts, fears of recession, and rising interest rates have taken their toll. While the broad market indices such as the DAX with 23% or the NASDAQ 100 technology index with 30% slipped into the red zone year-to-date, growth and financially intensive stocks, in particular, have suffered losses of over 70% in some cases. Despite corporate successes, the stocks have been sold off and are trading below their cash levels in some cases. In the long term, these are outstanding entry opportunities for patient investors.
Read